Keterangan
(IL-17) Six members have been identified: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E (also known as IL-25), and IL-17F.
Product Properties
|
Synonyms |
IL17B; Interleukin-17B |
|
Species |
Human |
|
Source |
HEK293 |
|
Sequence |
Gln21-Phe180 |
|
Accession |
Q9UHF5 |
|
Tag |
C-hFc |
|
Molecular Weight |
The protein has a predicted MW of 44.91 kDa. Due to glycosylation, the protein migrates to 50-60 kDa based on Bis-Tris PAGE result. |
|
Endotoxin |
< 1 EU/μg by the LAL method. |
|
Purity |
> 95% as determined by Bis-Tris PAGE and HPLC |
|
Activity |
ELISA Data: Immobilized Human IL-17B, hFc Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-IL-17B Antibody, hFc Tag with the EC50 of 18.0ng/ml determined by ELISA. |
|
Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
|
Appearance |
Lyophilized powder |
Shipping and Storage
-25 ~ -15 ° C storage, 1 year expiration date after receipt. After re-solution, store at 2 ~8 °C, 7 days expiration date. After re-dissolution, store at -85~-65°C, 3 months expiration date.
Compounding method
Centrifuge before opening the lid. Use distilled water to reconstitute lyophilized proteins at reconstitution concentrations greater than 100 μg/mL. it is recommended that proteins be portioned out for each experimental dosage upon first use to avoid repeated freeze-thawing.
Cautions
1. For your safety and health, please wear lab coat and disposable gloves.
2. This product is for scientific research purposes only.
Pembayaran & Keamanan
Informasi pembayaran Anda diproses dengan aman. Kami tidak menyimpan detail kartu kredit atau memiliki akses ke informasi kartu kredit Anda.
Pertanyaan
Anda mungkin juga menyukai
FAQ
Produk ini hanya untuk keperluan penelitian dan tidak ditujukan untuk penggunaan terapeutik atau diagnostik pada manusia atau hewan. Produk dan konten dilindungi oleh paten, merek dagang, dan hak cipta milik
Aplikasi tertentu mungkin memerlukan hak kekayaan intelektual pihak ketiga tambahan.